DaVita Inc. $DVA Shares Acquired by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of DaVita Inc. (NYSE:DVA) by 0.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 80,156 shares of the company’s stock after acquiring an additional 700 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.11% of DaVita worth $11,418,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Invesco Ltd. raised its holdings in DaVita by 3.4% in the 1st quarter. Invesco Ltd. now owns 1,642,947 shares of the company’s stock valued at $251,322,000 after acquiring an additional 53,402 shares during the last quarter. Northern Trust Corp grew its position in shares of DaVita by 20.2% in the first quarter. Northern Trust Corp now owns 890,632 shares of the company’s stock valued at $136,240,000 after purchasing an additional 149,858 shares during the period. Gates Capital Management Inc. increased its stake in DaVita by 0.7% in the first quarter. Gates Capital Management Inc. now owns 722,205 shares of the company’s stock valued at $110,476,000 after purchasing an additional 4,698 shares during the last quarter. Amundi lifted its position in DaVita by 16.0% during the first quarter. Amundi now owns 517,690 shares of the company’s stock worth $79,584,000 after buying an additional 71,304 shares during the period. Finally, Epoch Investment Partners Inc. boosted its stake in DaVita by 10.7% in the 1st quarter. Epoch Investment Partners Inc. now owns 407,921 shares of the company’s stock worth $62,400,000 after buying an additional 39,485 shares during the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Stock Performance

NYSE DVA opened at $123.55 on Thursday. The firm has a market capitalization of $8.72 billion, a price-to-earnings ratio of 12.72, a PEG ratio of 0.91 and a beta of 1.13. DaVita Inc. has a one year low of $115.39 and a one year high of $179.60. The company’s 50 day moving average price is $128.26 and its 200 day moving average price is $135.63.

DaVita (NYSE:DVA) last issued its earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing the consensus estimate of $3.17 by ($0.66). DaVita had a return on equity of 815.62% and a net margin of 5.80%.The company had revenue of $3.42 billion during the quarter, compared to analysts’ expectations of $3.43 billion. During the same period in the previous year, the company earned $2.59 EPS. DaVita’s quarterly revenue was up 4.8% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. Sell-side analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on DVA shares. Zacks Research cut DaVita from a “hold” rating to a “strong sell” rating in a report on Thursday, October 30th. Barclays decreased their target price on shares of DaVita from $149.00 to $143.00 and set an “equal weight” rating on the stock in a research report on Thursday, October 30th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of DaVita in a research report on Wednesday, October 8th. Bank of America cut their price target on shares of DaVita from $145.00 to $140.00 and set an “underperform” rating on the stock in a research note on Wednesday, September 10th. Finally, Cowen reissued a “hold” rating on shares of DaVita in a research note on Monday, November 3rd. Five analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus price target of $148.00.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.